Biontech Se Stock Operating Margin
| BNTX Stock | USD 86.40 0.06 0.07% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | 0.18 | 0.19 |
BioNTech | Operating Margin |
BioNTech SE Company Operating Margin Analysis
BioNTech's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current BioNTech Operating Margin | 0.40 % |
Most of BioNTech's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioNTech Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for BioNTech is extremely important. It helps to project a fair market value of BioNTech Stock properly, considering its historical fundamentals such as Operating Margin. Since BioNTech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioNTech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioNTech's interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
BioNTech Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, BioNTech SE has an Operating Margin of 0.4%. This is 101.14% lower than that of the Biotechnology sector and 100.36% lower than that of the Health Care industry. The operating margin for all United States stocks is 107.26% lower than that of the firm.
BioNTech Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNTech's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNTech could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics of similar companies.BioNTech is currently under evaluation in operating margin category among related companies.
BioNTech Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioNTech from analyzing BioNTech's financial statements. These drivers represent accounts that assess BioNTech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioNTech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8B | 6.4B | 15.7B | 34.3B | 23.0B | 24.1B | |
| Enterprise Value | 2.5B | 5.9B | 14.7B | 20.6B | 11.5B | 7.7B |
BioNTech Fundamentals
| Return On Equity | 0.0462 | ||||
| Return On Asset | 0.0262 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 4.2 B | ||||
| Shares Outstanding | 240.99 M | ||||
| Shares Owned By Insiders | 62.84 % | ||||
| Shares Owned By Institutions | 18.32 % | ||||
| Number Of Shares Shorted | 3.08 M | ||||
| Price To Earning | 5.19 X | ||||
| Price To Book | 0.96 X | ||||
| Price To Sales | 5.46 X | ||||
| Revenue | 3.82 B | ||||
| Gross Profit | 16.07 B | ||||
| EBITDA | 1.16 B | ||||
| Net Income | 1.19 B | ||||
| Cash And Equivalents | 9.33 B | ||||
| Cash Per Share | 38.30 X | ||||
| Total Debt | 219.1 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 85.17 X | ||||
| Cash Flow From Operations | 5.37 B | ||||
| Short Ratio | 4.33 X | ||||
| Earnings Per Share | 4.08 X | ||||
| Price To Earnings To Growth | 0.04 X | ||||
| Target Price | 118.5 | ||||
| Number Of Employees | 6.13 K | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 20.81 B | ||||
| Total Asset | 23.01 B | ||||
| Retained Earnings | 19.76 B | ||||
| Working Capital | 17.46 B | ||||
| Current Asset | 284.67 M | ||||
| Current Liabilities | 143.37 M | ||||
| Net Asset | 23.01 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
BioNTech Investors Sentiment
The influence of BioNTech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioNTech. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BioNTech's public news can be used to forecast risks associated with an investment in BioNTech. The trend in average sentiment can be used to explain how an investor holding BioNTech can time the market purely based on public headlines and social activities around BioNTech SE. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioNTech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioNTech's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioNTech's news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioNTech.
BioNTech Implied Volatility | 48.79 |
BioNTech's implied volatility exposes the market's sentiment of BioNTech SE stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if BioNTech's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that BioNTech stock will not fluctuate a lot when BioNTech's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioNTech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioNTech's short interest history, or implied volatility extrapolated from BioNTech options trading.
Pair Trading with BioNTech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.Moving together with BioNTech Stock
| 0.72 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against BioNTech Stock
| 0.71 | RZLT | Rezolute Trending | PairCorr |
| 0.66 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.63 | MRK | Merck Company Earnings Call Next Week | PairCorr |
| 0.63 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.59 | CELC | Celcuity LLC Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out BioNTech Piotroski F Score and BioNTech Altman Z Score analysis. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 4.08 | Revenue Per Share 15.873 | Quarterly Revenue Growth (0.65) | Return On Assets 0.0262 |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.